Bristol Myers Squibb is going all in on cancer with a wild $850M deal with Janux Therapeutics. The goal? Create tumor-activated drugs that dodge the nasty side effects of old-school treatments. Janux gets $50M upfront, and if all goes well, a ton more in milestones and royalties. BMS is betting big that Janux’s masked therapies could be a game-changer for solid tumors. Pharma drama, but make it science! #Health #BodyHealth #CancerResearch